A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

Recruiting now. Registry record last updated June 4, 2026.

Who can join: Adults 18+, are overweight, BMI 27+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 1 month.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Not ApplicableSponsor Novo Nordisk A/SDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 35,000

What this study is for

Primary condition: Overweight. Also studied in: Obesity.

Full scientific study title: Weight Loss in Adults Using Semaglutide (Real-world Study).

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Initiation of semaglutide for weight management during the study period.
Age more than or equal to (≥) 18 at treatment initiation
Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.
Other as defined in the protocol are applicable.

Key exclusion criteria

Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
Bariatric surgery at baseline.
Diabetes at baseline.
Pregnancy at baseline.

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Washington1 site

Novo Nordisk Investigational Site
Seattle, Washington

Follow this trial

We email you if NCT07627074 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: May 12, 2026. Expected completion: June 1, 2026. Last updated on ClinicalTrials.gov: June 4, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.